Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.51 |
| ▸ | CNR2 | P34972 | 6/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437144 | 0.96 | CNR1 (0.54) | CNR1CNR2SLC22A12ALDH1A1P2RX7 | |
| SCHEMBL24437195 | 0.92 | CNR1 (0.42) | CNR1CNR2LMNAHTTSMN1; SMN2 | |
| SCHEMBL24437154 | 0.92 | DYRK1A (0.49) | CNR1CNR2LMNAHTTSMN1; SMN2 | |
| SCHEMBL24437315 | 0.91 | CNR1 (0.45) | CNR1CNR2SLC22A12CFD | |
| SCHEMBL24437163 | 0.88 | CNR1 (0.51) | CNR1CNR2SLC22A12HTTSMN1; SMN2 | |
| SCHEMBL24437198 | 0.87 | CFD (0.42) | CNR1CNR2SLC22A12CFDLMNA | |
| SCHEMBL24437316 | 0.86 | CNR1 (0.53) | CNR1CNR2ALDH1A1P2RX7 | |
| SCHEMBL24437323 | 0.86 | PDE6D (0.42) | CNR1CNR2L3MBTL1 | |
| SCHEMBL24437232 | 0.86 | HTR3A (0.46) | CNR1CNR2LMNAHTTSMN1; SMN2 | |
| SCHEMBL24437134 | 0.84 | CNR1 (0.54) | CNR1CNR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | CNR1 940/4885CNR2 745/4885SLC22A12 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.